Literature DB >> 3516952

Prognostic factors for loco/regional control and metastasis and the impact on survival.

S Kramer, V A Marcial, T F Pajak, C J MacLean, L W Davis.   

Abstract

For the identification of predictive factors for local (head and neck) control and metastases and impact on survival in squamous cell cancer of the head and neck, we have used data from over 2000 patients from the Patterns of Care Study (PCS) and the Radiation Therapy Oncology Group (RTOG) studies. Complete local response (C.R.) is significantly related to T stage, N stage, general performance status (Karnofsky), and site of primary tumor. There is a strong association between T and N stage. T1N0 tumors showed a C.R. of 99%, whereas, T1N3 had a C.R. of 57%. T4N0 showed a C.R. of 75%, but this went down to 31% in the T4N3 lesions. Glottic tumors showed a C.R. of 96% versus the other sites, which ranged from 81% for the nasopharynx to 59% for the hypopharynx. Patients with a performance status (KPS) of less than 90% showed a C.R. of 60% versus 88% for AKPS 90% or higher. Absence of local recurrence after C.R. is significantly related to T stage, N stage, and the site of primary tumor (glottis versus the rest). The appearance of distant metastases is significantly related only to N stage and primary site. This relationship persists in control of loco/regional tumors. In Stages III & IV in non-glottic head and neck cancer, metastases as the cause of death play an increasingly important role. This can be as high as 30%. The appearance of new malignant tumors and death unrelated to cancer, that is, death related to lifestyle, assumes an important role in patients with advanced head and neck cancer. The number of advanced glottic larynx was too small to examine this question. The use of a surgical procedure in carcinomas of the anterior tongue and floor of the mouth was associated with a smaller percentage of infield recurrences at 2 years, than when radiation therapy alone was used (27% versus 88% p less than .01). The same observation was noted at 3 years in the glottic and supraglottic Stage III & IV tumors (p less than .01).

Entities:  

Mesh:

Year:  1986        PMID: 3516952     DOI: 10.1016/0360-3016(86)90065-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  [Reasons for the terms "radiosurgery" and "Gamma Knife"].

Authors:  K Hamm; G Surber
Journal:  HNO       Date:  2017-09       Impact factor: 1.284

2.  High-dose radiotherapy alone for patients with T4-stage laryngeal cancer.

Authors:  A Mucha-Małecka; K Składowski
Journal:  Strahlenther Onkol       Date:  2013-07-05       Impact factor: 3.621

3.  Photodynamic therapy with meta-tetrahydroxyphenylchlorin (Foscan) in the management of squamous cell carcinoma of the head and neck: experience with 35 patients.

Authors:  Kai Johannes Lorenz; Heinz Maier
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-03-17       Impact factor: 2.503

4.  Efficacy and safety of photodynamic therapy with temoporfin in curative treatment of recurrent carcinoma of the oral cavity and oropharynx.

Authors:  M Durbec; A Cosmidis; C Fuchsmann; A Ramade; P Céruse
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-08-29       Impact factor: 2.503

5.  [Squamous cell carcinoma of the head and neck. Photodynamic therapy with Foscan].

Authors:  K J Lorenz; H Maier
Journal:  HNO       Date:  2008-04       Impact factor: 1.284

6.  Predictive factors for long-term survival in head and neck squamous cell carcinoma patients with distant metastasis after initial definitive treatment.

Authors:  Ho-Seob Kang; Jong-Lyel Roh; Min-Ju Kim; Kyung-Ja Cho; Sang-wook Lee; Sung-Bae Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Cancer Res Clin Oncol       Date:  2015-09-04       Impact factor: 4.553

7.  Efficacy of Varunadi Ghritha (polyherbal compound) in treated head and neck cancer cases as a biological response modifier.

Authors:  Divya Ravindran; Indhu Hariharan; Richard Muwonge; Rejnish R Kumar; M Radhakrishna Pillai; Kunnambath Ramadas
Journal:  Ayu       Date:  2014-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.